AMRI to Highlight Sterile Manufacturing Capacity Expansion, New Technologies at CPhI

Company offerings include a complete suite of development and manufacturing capabilities

ALBANY, New York, Oct. 23, 2017 /PRNewswire/ -- AMRI, a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, will be highlighting its recent growth initiatives, technical capabilities and portfolio of active pharmaceutical ingredients (APIs) at CPhI Worldwide in Messe Frankfurt, Germany, 24-26 October 2017.

The addition of an aseptic pre-filled syringe filling line at the company's manufacturing facility in Albuquerque, N.M. is the most recent enhancement within the drug product business, and the investment reflects a growing interest by customers toward biologics, controlled substances, and complex compounds. According to David Stevens, senior vice president and head of Drug Product, AMRI's intent is to ensure that the company's drug product business has the capacity and technology to serve the increasing demand from customers and meet the evolving requirements for healthcare professionals and patients.

"AMRI's comprehensive suite of sterile dosage form development and manufacturing capabilities are designed to meet the needs of biopharma throughout the entire life cycle of their sterile drug product," said David Stevens. "This expansion – which will add capacity to manufacture roughly 50 million syringes per year – delivers more of the benefits that AMRI's best-in-class sterile dosage form capabilities and expertise has to optimize the path of projects from bench to market."

AMRI also continues to invest in expertise and technologies aimed at improving sterility assurance. Most recently, AMRI committed to installing LIGHTHOUSE laser-based headspace analyzer at its Albuquerque, N.M. site and expects it to be operational early 2018.

"Container closure integrity (CCI) plays a critical role in maintaining the sterility and stability of parenteral products and this technology allows us to perform 100% container closure integrity inspection of vials and places us at the forefront of the industry with respect to final product assurance for CCI," Stevens continued. "These investments underline our intent to remain a key player in the sterile dosage form development and manufacturing space."

In addition to highlighting AMRI's integrated sterile dosage form expertise, the company will also be highlighting its extensive portfolio of more than 240 APIs, including sterile and high potency APIs, steroids, generics, monobactams, boronic acids and controlled substances. CPhI Worldwide, co-located with ICSE, P-MEC, InnoPack and FDF 2017, is one of the industry's largest networking opportunities with more than 42,000 pharma industry professionals from more than 150 countries.

This year, CPhI will take place in Messe Frankfurt, and run between October 24th and 26th. Visit AMRI at stand 80G22.To access AMRI's full catalog of APIs, click here.

About AMRI
AMRI, a global contract research and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life. With locations in North America, Europe and Asia, AMRI's team combines scientific expertise and market-leading technology to provide a complete suite of solutions in Discovery, Development, Analytical and Solid State Services, API Manufacturing and Drug Product. For more information about AMRI, visit www.amriglobal.com.